Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Nurix Therapeutics and partner Roche have enrolled the first patient in the global Phase 3 DAYBreak CLL-306 trial evaluating Bexobrutideg for relapsed/refractory CLL/SLL. This is the first registrational Phase 3 trial for Bexobrutideg, a targeted protein degrader of BTK, and is designed to demonstrate superiority versus the current standard of care, pirtobrutinib.
Key figures
- Drug Name
- Bexobrutideg (NX-5948)
- Phase Of Trial
- Phase 3
- Comparator drug
- pirtobrutinib
- Patients targeted
- 620
- Primary endpoints
- objective response rate (ORR) and progression free survival (PFS)
- Randomization ratio
- 1:1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.